Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtre
Ajouter des filtres








Gamme d'année
1.
Indian J Exp Biol ; 2000 Sep; 38(9): 895-900
Article Dans Anglais | IMSEAR | ID: sea-63119

Résumé

This study was designed to investigate the influence of volatile oil pretreated skin on in vitro permeation from films containing ionized and dodecylamine ion-paired diclofenac sodium (DS). The involvement of skin cholesterol was investigated to determine its possible role in enhancing the permeation of ion-paired DS. Cardamom oil produced the maximum (10 x) in vitro permeation enhancement for ion-paired DS. The carrageenan induced rat paw oedema reduction (up to 12 hr) by cardamom oil was comparable to that of diclofenac injection (s c). Leaching of cholesterol from excised skin in addition to increased partition coefficient following volatile oil skin pretreatment appears to be responsible for in vitro permeation enhancement of DS. Whereas, a mild barrier perturbation effect due to altered cholesterol levels following pretreatment with volatile oils appears to increase the permeation of ion-paired DS across viable skin, thereby producing significant reduction of carrageenan induced paw oedema.


Sujets)
Administration par voie cutanée , Animaux , Anti-inflammatoires non stéroïdiens/pharmacocinétique , Marqueurs biologiques/analyse , Cholestérol/métabolisme , Diclofenac/pharmacocinétique , Oedème/induit chimiquement , Épiderme/métabolisme , Mâle , Huile essentielle/pharmacologie , Perméabilité , Rats , Lignées consanguines de rats , Rat Wistar , Peau/métabolisme , Absorption cutanée/effets des médicaments et des substances chimiques , Solubilité , Véhicules pharmaceutiques/pharmacocinétique
2.
Article Dans Anglais | IMSEAR | ID: sea-89703

Résumé

The management of diabetic hypertension requires meticulous selection of agents in the antihypertension armamentorium. There may be several associated factors to be considered while treating a hypertensive diabetic. These include hyperglycemia, dyslipidemia, proteinuria, left ventricular hypertrophy and heart failure to name a few. Losartan is the first of a new class of agents in the list of antihypertensive drugs. By its selective angiotension II receptor (subtype AT1) blocking action it is postulated to bring about a more complete inhibition of the renin-angiotensin system. Thus, it might produce all the benefits of angiotensin converting enzyme (ACE) inhibitor therapy with the freedom from cough so commonly seen with the use of ACE inhibitors. This review attempts to analyze the possible benefits of losartan therapy in diabetes.


Sujets)
Complications du diabète , Diabète/traitement médicamenteux , Humains , Hypertension artérielle/traitement médicamenteux , Losartan/effets indésirables , Essais contrôlés randomisés comme sujet , Facteurs de risque , Résultat thérapeutique
SÉLECTION CITATIONS
Détails de la recherche